Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.

Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE; American Society of Clinical Oncology; American Society of Hematology.

J Clin Oncol. 2008 Jan 1;26(1):132-49. Epub 2007 Oct 22. Erratum in: J Clin Oncol. 2008 Mar 1;26(7):1192.

PMID:
17954713
2.

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.

Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE.

Blood. 2008 Jan 1;111(1):25-41. Epub 2007 Oct 22. Review. Erratum in: Blood. 2008 Apr 1;111(7):3909.

3.

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Society of Clinical Oncology; American Society of Hematology.

J Clin Oncol. 2010 Nov 20;28(33):4996-5010. doi: 10.1200/JCO.2010.29.2201. Epub 2010 Oct 25. Review.

PMID:
20975064
4.

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee.

Blood. 2010 Nov 18;116(20):4045-59. doi: 10.1182/blood-2010-08-300541. Epub 2010 Oct 25. Review.

5.

Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.

Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.

J Manag Care Pharm. 2008 Nov-Dec;14(9):858-69.

6.

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF.

Cochrane Database Syst Rev. 2014 Dec 8;(12):CD010590. doi: 10.1002/14651858.CD010590.pub2. Review.

PMID:
25486075
7.

Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.

Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, Van Belle S.

Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18. Review.

8.

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2016 Feb 4;2:CD009624. doi: 10.1002/14651858.CD009624.pub2. Review.

PMID:
26845108
9.

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS; American Society of Clinical Oncology; Americcan Society of Hematology.

Blood. 2002 Oct 1;100(7):2303-20.

10.

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT.

Clin Ther. 2006 Jun;28(6):801-31. Review. Erratum in: Clin Ther. 2007 May;29(5):985-6. Clin Ther. 2007 May;29(5):985-986.

PMID:
16860166
11.
12.

Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.

Shord SS, Cuellar S.

J Am Pharm Assoc (2003). 2008 Jul-Aug;48(4):487-93. doi: 10.1331/JAPhA.2008.07110.

PMID:
18653424
13.

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.

Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C.

Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. Review.

14.

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

Cersosimo RJ, Jacobson DR.

Ann Pharmacother. 2006 Jan;40(1):58-65; quiz 169-70. Epub 2005 Dec 6. Review.

PMID:
16332942
15.

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.

Clin Ther. 2003 Nov;25(11):2781-96.

PMID:
14693304
16.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
18.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.

Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K.

Med Oncol. 2012 Sep;29(3):2291-9. doi: 10.1007/s12032-011-0103-x. Epub 2011 Nov 13.

PMID:
22081263
19.

The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.

Polsky D, Eremina D, Hess G, Hill J, Hulnick S, Roumm A, Whyte JL, Kallich J.

Pharmacoeconomics. 2009;27(9):755-65. doi: 10.2165/11313860-000000000-00000.

PMID:
19757869
20.

Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.

Siegel J, Jorgenson J, Johnson PE, Brophy DF, Comstock T, Feng A, Audhya P.

Am J Health Syst Pharm. 2008 Sep 15;65(18):1711-9. doi: 10.2146/ajhp070526.

PMID:
18768997

Supplemental Content

Support Center